title: Randomized controlled trial comparing changes in serum prolactin and weight among female patients with first-episode schizophrenia over 12 months of treatment with risperidone or quetiapine.
abstract: BACKGROUND
  Increased serum prolactin and weight gain are common side effects of atypical antipsychotics but few studies have assessed the long-term pattern of these adverse effects.
  
  
  OBJECTIVE
  Compare the effects of risperidone and quetiapine on serum prolactin and weight over 12 months of treatment among female patients with first-episode schizophrenia.
  
  
  METHODS
  Eighty female inpatients with first-episode schizophrenia were randomly assigned to receive risperidone (n=40) or quetiapine (n=40) for 12 months. Prolactin concentration, weight and height were measured one day before starting treatment and 1, 3, 6, 9 and 12 months after initiating treatment. Severity of symptoms was assessed at the same time periods using the Positive and Negative Syndrome Scale (PANSS).
  
  
  RESULTS
  Thirty-one patients in the risperidone group and 33 patients in the quetiapine group completed the 12 months of treatment. PANSS scores decreased at each follow-up assessment for both groups; the improvement was significantly greater in the risperidone group after 3 months and 6 months of treatment but by the 9th month of treatment the level of improvement in the two groups was similar. In the quetiapine group serum prolactin remained stable throughout the 12 months but in the risperidone group the serum prolactin level increased 3.5- to 5.2-fold over the one-year follow-up. Weight gain was seen in both groups, particularly during the first 3 months of treatment: 62% of the increase in BMI in both groups had occurred by the end of the 3rd month of treatment. No between-group differences in weight changes were observed. The correlation between changes in weight and changes in prolactin levels were weakly positive: rs=0.17(p=0.104) in the risperidone group and r=0.07 (p=0.862) in the quetiapine group.
  
  
  CONCLUSIONS
  Risperidone and quetiapine had similar efficacy in the first year of treatment of first-episode schizophrenia though risperidone was more rapidly effective. Use of risperidone was associated with chronic hyperprolactinemia but this did not occur with quetiapine. Long-term use of both drugs was associated with sustained weight gain; the timing and magnitude of the weight gain is similar for the two drugs. Weight gain was not strongly related to changes in prolactin levels.
authors.affiliation: Psychiatry Department, Third People's Hospital of Huzhou, Zhejiang Province, China.
authors.forename: Jianjun
authors.initials: J
authors.lastname: Liu
authors.affiliation: Psychiatry Department, Third People's Hospital of Huzhou, Zhejiang Province, China.
authors.forename: Jushui
authors.initials: J
authors.lastname: Sun
authors.affiliation: Psychiatry Department, Third People's Hospital of Huzhou, Zhejiang Province, China.
authors.forename: Xinghua
authors.initials: X
authors.lastname: Shen
authors.affiliation: Psychiatry Department, Third People's Hospital of Huzhou, Zhejiang Province, China.
authors.forename: Weigang
authors.initials: W
authors.lastname: Guo
authors.affiliation: Psychiatry Department, Third People's Hospital of Huzhou, Zhejiang Province, China.
authors.forename: Shengli
authors.initials: S
authors.lastname: Zhi
authors.affiliation: Psychiatry Department, Third People's Hospital of Huzhou, Zhejiang Province, China.
authors.forename: Guangming
authors.initials: G
authors.lastname: Song
authors.affiliation: Psychiatry Department, Third People's Hospital of Huzhou, Zhejiang Province, China.
authors.forename: Qiuxia
authors.initials: Q
authors.lastname: Xu
authors.affiliation: Laboratory Department, Third People's Hospital of Huzhou, Zhejiang Province, China.
authors.forename: Juanfen
authors.initials: J
authors.lastname: Song
keywords: China; first-episode; long-term follow-up; quetiapine; risperidone; schizophrenia; weight gain
references.citation: Clin Schizophr Relat Psychoses. 2012 Oct;6(3):115-21
references.pmid: 23006236
references.citation: J Clin Psychopharmacol. 2009 Jun;29(3):278-83
references.pmid: 19440083
references.citation: Endokrynol Pol. 2006 Nov-Dec;57(6):656-62
references.pmid: 17253440
references.citation: Schizophr Bull. 2009 Sep;35(5):937-48
references.pmid: 18400811
references.citation: Prog Neuropsychopharmacol Biol Psychiatry. 2013 Jan 10;40:260-6
references.pmid: 23085073
references.citation: BMC Musculoskelet Disord. 2009 Jan 01;10:1
references.pmid: 19118498
references.citation: J Psychiatr Res. 2012 Apr;46(4):540-8
references.pmid: 22316639
references.citation: J Cell Physiol. 2012 Aug;227(8):3001-6
references.pmid: 22105468
references.citation: Prog Neuropsychopharmacol Biol Psychiatry. 2011 Mar 30;35(2):490-6
references.pmid: 21146575
references.citation: Acta Psychiatr Scand. 2007 Apr;115(4):277-85
references.pmid: 17355518
references.citation: J Clin Psychiatry. 2004 Dec;65(12):1607-18; quiz 1590, 1760-1
references.pmid: 15641865
references.citation: J Psychopharmacol. 2008 Mar;22(2 Suppl):12-9
references.pmid: 18477617
references.citation: CNS Drugs. 2011 Dec 1;25(12):1035-59
references.pmid: 22133326
references.citation: Handb Exp Pharmacol. 2012;(212):135-64
references.pmid: 23129331